Guglielmo Parisi, Francesco Gelormini, Veronica Vallino, Federico Ricardi, Paola Marolo, Enrico Borrelli, Ugo De Sanctis, Michele Reibaldi
{"title":"Treatment of AMD-related macular neovascularization in a patient with silicone oil tamponade.","authors":"Guglielmo Parisi, Francesco Gelormini, Veronica Vallino, Federico Ricardi, Paola Marolo, Enrico Borrelli, Ugo De Sanctis, Michele Reibaldi","doi":"10.1177/11206721251333273","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> to present a case of active neovascular AMD treated with anti-VEGF drug in the presence of silicone oil. <b>Study design:</b> case report. <b>Results:</b> A 69-year-old male was referred to the surgical retina service due to a sudden loss of peripheral vision in the left eye (LE). Biomicroscopic examination revealed the presence of geographic atrophy in the right eye (RE) and a macula-on retinal detachment in the far periphery with drusen at the posterior pole in LE. Combined OCT-OCTA examination demonstrated the presence of non-active type 1 MNV in the LE. The patient underwent a 25-gauge pars plana vitrectomy (PPV) with silicone oil tamponade in the LE. Post-operative follow-up involved clinical and instrumental monitoring every 7 days for the first 3 months and every 15 days in the fourth month, until the removal of the silicone oil. During the follow-up, we detected the reactivation of type 1 MNV in the LE, and as a result, the patient received three monthly Ranibizumab injections in the LE, in conjunction with the removal of silicone oil from the vitreous cavity at the at the fourth month postoperatively. <b>Conclusions</b>: our case report highlights the clinical response to three injections of intravitreal Ranibizumab therapy in managing active neovascular AMD with SO tamponade. The duration of intravitreal Ranibizumab therapy in SO may not differ significantly compared to an eye with intact vitreous humor.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"NP59-NP63"},"PeriodicalIF":1.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721251333273","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: to present a case of active neovascular AMD treated with anti-VEGF drug in the presence of silicone oil. Study design: case report. Results: A 69-year-old male was referred to the surgical retina service due to a sudden loss of peripheral vision in the left eye (LE). Biomicroscopic examination revealed the presence of geographic atrophy in the right eye (RE) and a macula-on retinal detachment in the far periphery with drusen at the posterior pole in LE. Combined OCT-OCTA examination demonstrated the presence of non-active type 1 MNV in the LE. The patient underwent a 25-gauge pars plana vitrectomy (PPV) with silicone oil tamponade in the LE. Post-operative follow-up involved clinical and instrumental monitoring every 7 days for the first 3 months and every 15 days in the fourth month, until the removal of the silicone oil. During the follow-up, we detected the reactivation of type 1 MNV in the LE, and as a result, the patient received three monthly Ranibizumab injections in the LE, in conjunction with the removal of silicone oil from the vitreous cavity at the at the fourth month postoperatively. Conclusions: our case report highlights the clinical response to three injections of intravitreal Ranibizumab therapy in managing active neovascular AMD with SO tamponade. The duration of intravitreal Ranibizumab therapy in SO may not differ significantly compared to an eye with intact vitreous humor.
期刊介绍:
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.